"Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry." by Daniel Aaron Pollyea

Selected Works of John M. Pagel, MD, PhD

Article

Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry.

Journal of Clinical Oncology (2017)

Daniel Aaron Pollyea, University of Colorado Boulder
Tracy George, University of New Mexico
Kathryn M Foucar, University of New Mexico
Harry Paul Erba, University of Alabama at Birmingham
Michael A. Thompson, Aurora Advanced Healthcare, Milwaukee, WI;
Mehrdad Abedi, University of California, Davis
Gail J. Roboz, NewYork–Presbyterian Hospital
Danny Landau, University of Florida Health
John M. Pagel, Swedish Cancer Institute, Seattle, WA;
Karen Seiter, New York Medical College
Christopher R. Cogle, University of Florida
Melissa Nifenecker, Celgene
Arlene S. Swern, Celgene
Pavel Kiselev, Celgene
Mary M. Sugrue, Celgene

Link

Disciplines

Publication Date

May 20, 2017

DOI

10.1200/jco.2017.35.15_suppl.7022

Citation Information

Daniel Aaron Pollyea, Tracy George, Kathryn M Foucar, Harry Paul Erba, et al.. "Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry." Journal of Clinical Oncology Vol. 35 (2017) p. 7022 - 7022
Available at: http://works.bepress.com/john-pagel/305/